The Hemerion team brings together physicists, biologists and surgeons specialized in oncology. We develop innovative therapeutic solutions, at the crossroads of surgery, biology and photonics. The scientific and medical team is complemented by seasoned professionals in business management, regulatory functions and clinical development.
Management
Maximilien Vermandel,
PhD, Physics
CEO, Founder
- Over 18 years of research in physics and neurosurgery
- Head of the medical physics dept of the University Hospital of Lille (France)
- Deputy director of OncoThAI Lab (Inserm U1189)
- Program manager for General Electric Healthcare joint research program
- Team Leader of the glioblastoma research and development program at OncoThAI Lab
Clément Dupont,
PhD, Physics
CTO, Co-Founder
- Management of preclinical investigations in glioblastoma studies
- Designer of the medical devices used in the first-in-human clinical trial evaluating the Hemerion Technology
- Deputy team leader of the Synaps project from OncoThAI Lab
Michel Andraud,
MSc, Business School
CFO, Co-Founder
- Transition manager over 15 years after 18 years as CFO in various industrial companies, (Entrelec, gmp-orphan SA, DI Finances) and in mergers and acquisitions
- Cash management oriented
- CFO of OP2 drugs SA
Scientific Board
Pr. Nicolas Reyns,
PhD, MD, Neurosurgery
Co-Founder
- Head of the neurosurgery oncology dept of the Univ. Hosp. of Lille
- Co-inventor of the Hemerion technology
- Over 100 scientific papers
Pr. Serge Mordon,
PhD, Physics
Co-Founder
- Full time researcher in laser therapy over 40 years at Inserm
- Former Director of OncoThAI Lab (Inserm U1189)
- Over 500 scientific papers
Pr. Costas G. Hadjipanayis,
PhD, MD, Neurosurgery
- Director, UPMC Center for Image-Guided Neurosurgery
- Former Director of Neurosurgical Oncology for the Mount Sinai Health System (NYC, NY, USA)
- Helped lead the FDA approval of Gleolan
- Over 100 scientific papers